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INTRODUCTION
The typical treatment of vesicoureteral reflux (VUR) 
is to wait for improvement of  the reflux with bladder 
maturation. However, a prerequisite to deciding to wait is 
the absence of ongoing renal parenchymal damage. To avoid 
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renal damage, patients with VUR must take prophylactic 
antibiotics, manage constipation, or be periodically checked 
for urinary tract infection (UTI). Because endoscopic 
treatment (ET) is simple, has low morbidity, and has 
the advantage that patients can discontinue antibiotic 
prophylaxis, it is supported as a first-line treatment for 
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VUR [1,2]. Moreover, ET has replaced most open surgeries 
owing to its high success rate, simplicity, and convenience [3]. 
However, ET success is often short-lived [4]. In most studies, 
the success rate of ET is determined 3 months after surgery. 
Thus, if follow-up periods were longer, the recurrence rate 
may be higher. Unlike open or laparoscopic surgery, ET is 
performed on the assumption that it may fail. Therefore, the 
natural course after ET failure is essential to choosing the 
treatment.
Many studies have investigated the causes of failed ET 
or the effect of performing a second ET on the patient [5-
9]. However, studies about the natural course of persistent 
or recurrent VUR after ET failure are extremely rare. In 
addition, the role of voiding dysfunction in the resolution of 
VUR and the success rate of surgical procedures for VUR 
have been well elucidated [10-12]. However, the relationship 
between bladder overactivity and ET success in VUR is still 
controversial [10,13].
We evaluated the natural course of  VUR after ET 
failure. Furthermore, we evaluated the relationship between 
involuntary detrusor contraction (IDC) and resolution of 
VUR and ET success.
MATERIALS AND METHODS
Following Institutional Review Board approval of the 
study, we retrospectively reviewed the medical records of 
children diagnosed with VUR who underwent ET from 
January 2006 to December 2009. The patients had been 
followed up for more than 1 year after ET. Patients with 
prior antireflux surgery, duplex system, ureterocele, ectopic 
ureter, megaureter, neurogenic abnormalities, or structural 
anomalies of the bladder and urethra were excluded. A total 
of 165 patients with 260 ureters were included in this study.
All patients underwent urinalysis, ultrasonography, 
dimercaptosuccinic acid (DMSA) renal scan, and voiding 
cystourethrography (VCUG). VCUG and DMSA renal 
scan were performed after the resolution of  fever and 
conf irmation of  a negative urine culture. VUR was 
graded by using the system defined by the international 
Reflux Study Committee [14]. Follow-up ultrasonography 
was performed at 1 month after ET and we observed 
the presence or absence of  a Deflux (hyaluronic acid/
dextranomer) mound (Salix Pharmaceuticals, Raleigh, NC, 
USA). VCUG and DMSA were performed at 6 months after 
ET. For patients who had remnant VUR after ET, VCUG 
was performed every 1 year until spontaneous resolution of 
VUR.
A urodynamic study (UDS) was performed on all 
children with prior ET from January 2008. UDS was 
performed by using Medtronic multi-P cystometry (Duet, 
Medtronic, Denmark), with a 6-Fr double-lumen urethral 
catheter and an 8-Fr rectal tube. No patient was placed 
under sedation. The infusion rate was set at 10% of expected 
bladder capacity per minute and we used ≥30 mL (30×age 
in years) to calculate the expected bladder capacity [15]. 
The temperature of the infusion saline was set to 30oC and 
maintained so. Bladder capacity was defined as the volume 
at which the patients started to void. IDC was defined 
as any involuntary contraction during the filling phase. 
Dysfunctional voiding (DV) was defined as an intermittent 
or fluctuating uroflow rate from involuntary intermittent 
contractions of the striated muscle of the external urethral 
sphincter or pelvic floor during voiding [16].
Indications for ET were breakthrough UTI, noncompliance 
with medication, development of new renal scars, or decreased 
renal function over grade II VUR. Grade I VUR was treated 
only when it was associated with contralateral high-grade 
VUR. To avoid sample bias, the ET group included only 
patients who received Deflux hyaluronic acid/dextranomer 
injection.
Patients received general anesthesia before undergoing 
ET. We used an 8- to 9.8-Fr cystoscope, which facilitated 
hyaluronic acid/dextranomer injection via a prefilled 
polycarbonate syringe and cannula (3.5 Fr×35 cm.). Surgical 
procedures were performed on a case-by-case basis at the 
discretion of the surgeon by the subureteric transurethral 
injection (STING) method or hydrodistention-implantation 
technique (HIT). The success of  ET was determined at 6 
months after surgery. Success was defined as no VUR or 
grade I VUR on VCUG.
Statistical analyses were performed by using IBM 
SPSS Statistics ver. 19.0 (IBM Co., Armonk, NY, USA). We 
compared variables by using Student t-test, the chi-square 
test, and Fisher exact test. A p-value of less than 0.05 was 
considered statistically significant.
RESULTS
The patients’ mean age at diagnosis was 22.34±26.62 
months (range, 0.9–96 months). The mean VUR grade was 
2.76±0.94. Photon defects were seen in 96 kidney units (36.9%).
According to the results of  the VCUG performed 6 
months after ET, we divided patients into two groups: 
success or failure. ET success was seen in 184 of 260 ureters 
(70.8%). There were no signif icant dif ferences in sex, 
laterality, or febrile UTI between the two groups. However, 
the preoperative VUR grade was 2.59±0.95 in the success 
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group and 3.19±0.80 in the failure group (p=0.012). Photon 
defects were seen in 61 kidney units (33.1%) in the success 
group and in 35 units (46.1%) in the failure group (p=0.05). 
The indications for ET were breakthrough UTI (n=241), 
noncompliance with medication (n=7), and decreased renal 
function or newly developed renal scarring (n=12). There was 
no significant difference between the success and failure 
groups in the indications for ET (p=0.302). The mean injected 
volume of hyaluronic acid/dextranomer was not significantly 
different between the success and failure groups: 0.97±0.52 
and 1.16±0.64, respectively (p=0.42). When the mound 
morphology was a volcano shape, ET success was observed 
in 78.7% of cases. The percentage of material mound seen in 
postoperative ultrasonography was significantly different in 
the success and failure groups (p=0.002) (Table 1).
Those with a higher grade VUR had a lower ET success 
rate. The success rates, according to reflux grade, were 100% 
(26/26), 79.7% (55/69), 66.4% (73/110), 57.1% (28/49), and 33.3% 
(2/6) for grades I to V, respectively.
In cases in which UDS was performed, IDC was observed 
in 35 of 163 ureters (21.4%), but IDC did not show a significant 
correlation with ET success. The mean maximum cystometric 
Table 1. Characteristics of the ET success versus the ET failure group
Characteristic ET success ET failure p-value
Ureters 184 (70.8) 76 (29.2)
Age at surgery (mo) 38.11±28.88 34.05±25.32 0.288
Sex
    Male 107 (58.2) 38 (50.0) 0.229
    Female 77 (41.8) 38 (50.0)
Laterality
    Unilateral 37 17 0.758
    Bilateral 73 30
Febrile UTI 174 (94.6) 71 (93.4) 0.453
Indications for ET 0.302
    Breakthrough UTI 173 (71.8) 68 (29.2)
    Decreased renal function or newly developed renal scar 6 (50.0) 6 (50.0)
    Noncompliance with medication 5 (71.4) 2 (28.6)
VUR grade 2.59±0.95 3.19±0.80 0.012
Photon defect 61 (33.1) 35 (46.1) 0.05
Injection volume 0.97±0.52 1.16±0.64 0.42
Mound morphology <0.001
    Volcano shape 163 (78.7) 44 (21.3)
    Other shape 21 (39.6) 32 (60.4)
Postoperative US finding of mound in bladder 0.002
    Visualized 132 (77.2) 39 (22.9)
    Not visualized 52 (58.4) 37 (41.6)
Values are presented as mean±standard deviation or number (%).
ET, endoscopic treatment; UTI, urinary tract infection; VUR, vesicoureteral reflux; US, ultrasonography.
Table 2. Comparison of the urodynamic parameters between the ET success and ET failure groups
Parameter ET success (n=99) ET failure (n=64) p-value
IDC 9 26 0.064
Age (mo) 39.2±28.1 34.4±25.9 0.288
MCC (mL) 140.2±77.2 153.3±99.6 0.373
% of MCC/EBC 115.8±56.3 121.9±64.0 0.529
MaxPdet (cmH2O) 67.2±35.2 60.0±38.4 0.264
PVR (mL) 15.7±24.8 18.2±22.8 0.516
DV (No. of ureters) 10 5 0.421
Values are presented as number or mean±standard deviation.
ET, endoscopic treatment; IDC, involuntary detrusor contraction; MCC, maximum cystometric capacity; EBC, estimated bladder capacity; MaxPdet, 
maximal detrusor pressure; PVR, postvoid residual; DV, dysfunctional voiding.
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capacity, maximum detrusor pressure at voiding, postvoiding 
residual urine volume, and the number of cases of DV were 
also not significantly different between the success and 
failure groups (Table 2).
Postoperative UTI was observed in 5% of the ET success 
group and 52% of the ET failure group. Persistent VUR was 
observed in 76 ureters (29.2%) after ET. Among these, 43 
ureters (56.6%) were treated conservatively and 33 ureters 
(43.4%) required surgical treatment. Fifty-two of  the 76 
ureters (68.4%) were observed to have a downgrading of 
VUR, based on comparisons between preoperative VCUG. 
In 18 ureters (23.7%), VUR resolution was observed at a 
mean time of 16.3 months after ET; the other 25 ureters 
(32.9%) were followed up with conservative treatment. For 
the conservative treatment group after ET failure, the 
mean VUR grade decreased from 3.13±0.19 to 2.04±0.04. In 
the conservative treatment group after ET failure, volcano 
shape mounds were seen in 77.2% (Table 3). 
The results of Kaplan-Meier survival analysis showed 
that the resolution time of  VUR in the ET group was 
significantly shorter than in the conservative treatment 
groups (9.27±0.75 months for the ET group, 18.8±0.97 
months for the conservative treatment group, p<0.001). The 
conservative treatment group included 309 ureters diagnosed 
with VUR and followed up conservatively in our hospital in 
the same follow-up period. In looking at the curve of VUR 
resolution in the ET failure group, VUR resolution occurred 
at 21.01±2.36 months after ET, which was not significantly 
different from the 18.8±0.97 months for the conservative 
treatment group (p=0.42) (Fig. 1).
In cases with secondary surgical treatment who suffered 
a recurrent febrile UTI, newly developed renal scar, or 
decreased renal function after ET failure, secondary ET 
was performed in 19 ureters and ureteral reimplantation 
was performed for 14 ureters. When newly developed renal 
scarring or decreased renal function was observed, we 
performed ureteral reimplantation rather than a secondary 
ET. The mean time to a secondary operation was 12.8 months 
(range, 5–32 months) after ET. The success rate of secondary 
Table 3. Characteristics of the conservative treatment group versus the secondary procedure group after ET failure
Characteristic Conservative treatment 2nd Procedure p-value
Ureters 43 33
Indications for ET 0.309
    Breakthrough UTI 39 (57.4) 29 (42.6)
    Decreased renal function or newly developed renal scar 3 (50.0) 3 (50.0)
    Noncompliance with medication 2 (100) 0 (0)
VUR grade 2.93±0.99 3.37±0.75 0.038
Mound morphology <0.001
    Volcano shape 34 (77.3) 10 (22.7)
    Other shape 10 (31.2) 22 (68.8)
Postoperative US finding of mound in bladder 0.163
    Visualized 26 (66.7) 13 (33.3)
    Not visualized 18 (48.7) 19 (51.4)
IDC 0.025
    Normal 35 (63.6) 20 (36.4)
    Positive IDC 2 (22.2) 7 (77.8)
Values are presented as number (%) or mean±standard deviation.
ET, endoscopic treatment; UTI, urinary tract infection, VUR, vesicoureteral reflux; US, ultrasonography; IDC, involuntary detrusor contraction.
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Fig. 1. Vesicoureteral reflux (VUR) resolution curve. VUR resolution oc-
curred in 21.01±2.36 months after endoscopic treatment (ET), which was 
not significantly different from 18.8±0.97 months for the conservative 
treatment group (p=0.42). Number of patients in each group: conserva-
tive treatment (Tx) group (n=309), ET group (n=260), and ET failure group 
(n=76).
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ET was 68.4%. Among six ureters with failed secondary ET, 
two were followed up conservatively and the other four 
underwent ureteral reimplantation (Fig. 2).
In cases with available UDS from the ET failure 
group, IDC was observed in 2 of 37 ureters (5.4%) in the 
conservative treatment group and in 7 of 27 (25.9%) in the 
secondary procedure group (p=0.025) (Table 3). IDC was 
found in 1 of  9 ureters (11.1%) among the secondary ET 
success group, whereas in the secondary ET failure group, 4 
of 6 (66.7%) had accompanying IDC.
DISCUSSION
ET was first described by Matouschek [17], O’Donnel and 
Puri [18], who further popularized this method. Stenberg and 
Lackgren [19] were the first to describe the application of 
Deflux hyaluronic acid/dextranomer. Enthusiasm for this 
material, which culminated in its approval by the U.S. Food 
and Drug Administration, increased the rate of development 
of the product. Since the mid-2000s, ET has been used in 
88% of surgical interventions for VUR [3]. Numerous reports 
have investigated hyaluronic acid/dextranomer injections 
in the context of primary VUR and redo cases, highlighting 
the efficacy of the procedure. Recently, Kirsch et al. [20] 
presented a hydrodistention modification that yielded cure 
rates as high as 92% for primary low-grade VUR. 
However, Lee et al. [4] concluded that ET success might 
be temporary and that long-term follow-up is necessary, 
even though post-ET VCUG does not show VUR. In their 
series of reports, an initial success rate (6 to 12 weeks) of 
73% was found, but after 1 year of follow-up, they found 39 
of 150 ureters had recurring VUR with an overall success 
rate of 46%. Sedberry-Ross et al. [6] reported that 12 of 45 
(27%) of their ET success patients had a febrile UTI on long-
term follow-up and 10 of 12 (92%) of these were found to 
have a recurrence of VUR. Like this study, many studies 
reported that mound morphology, preoperative VUR grade, 
and material presence on postoperative ultrasonography 
were factors predicting ET success [21-23]. In most studies, 
ET success was judged by VCUG after 3 months of ET, and 
patients discontinued taking antibiotics after confirmation 
of success [24,25]. However, we performed VCUG 6 months 
after ET and prophylactic antibiotics were discontinued 
immediately after ET. We deferred postoperative VCUG 
to 6 months after ET because we have not seen febrile 
UTIs develop between 3 and 6 months after ET. A longer 
interval between ET and post-ET VCUG is more effective 
in determining whether ET is successful. In our study, we 
found a 70.8% success rate of ET, which is not inferior to 
other series using VCUG within 3 months after ET.
We regard it difficult to evaluate the result of ET in 
the management of VUR owing to the characteristics of 
VUR. VUR can spontaneously resolve with time, although 
VUR of grade V generally needs surgical correction. For 
the cases that reported the disappearance of  VUR after 
ET, this finding may be the result of a natural resolution 
of VUR rather than a therapeutic effect of ET. In other 
words, persistent or recurrent VUR may also resolve 
without further treatment if  febrile UTI does not occur. 
In many studies, when ET failure was observed, repeat 
ET was considered [8,26]. In our study, 18 of the 76 ureters 
(23.7%) with persistent VUR at 6 months after ET reported 
VUR resolution an average of 16.3 months after ET. The 
other 25 ureters (32.8%) were treated conservatively. This 
showed that some cases did not require additional surgical 
treatment even with ET failure. The Kaplan-Meier survival 
Fig. 2. Algorithm of treatment for failed endoscopic treatment (ET). A secondary procedure was performed in cases of recurrent febrile urinary tract infec-
tion or newly developed renal scarring or a decrease in renal function after ET failure. When a newly developed renal scar or decreased renal function was 
observed, we performed ureteral reimplantation rather than secondary ET.
18 Spontaneous resolution
25 Conservative treatment
43 Conservative treatment
33 2nd procedure
19 2 ETnd
14 Open surgery
2 Conservative treatment
4 Open surgery
13 Success
6 Failure
76 ET failure
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curve showed that the curve of the natural course after 
ET failure was not worse than the spontaneous resolution 
curve for VUR, 21.01±2.36 and 18.8±0.97 months, respectively 
(p=0.42). 
Many studies have shown that the success rate of ET 
differs according to whether the STING or HIT method is 
used [20,22]. In this study, the success rate was higher with 
HIT than with STING. However, HIT (6 ureters) and double 
HIT (6 ureters) was performed in only 12 ureters (4.6%); 
STING was performed in most ureters (248 ureters, 95.4%). 
Therefore, we did not compare the success rate according to 
the method used. 
In many studies, voiding dysfunction is thought to 
be the causal factor for VUR as well as the main factor 
affecting VUR progress [10-12]. Before children reach the 
age of bladder control, most studies show that low-capacity, 
high voiding pressure and incoordination at voiding are 
normal findings [27,28]. Most patients in the present study 
were younger than the age of bladder control; thus, their 
IDCs were unlikely to be pathological but could have 
affected VUR. IDC was not associated with ET success 
in this study; however, the secondary procedure rate was 
higher in the IDC-positive group (25.9%) than in the IDC-
negative group (5.4%). That is, IDC did not influence ET 
success but indirectly increased the need for a secondary 
procedure through other factors like febrile UTI and 
further renal damage. Furthermore, IDC was seen more 
frequently in cases in the secondary ET failure group (failure 
in 66.7% vs. success in 11.1%). One possible explanation for 
the discrepancy between the role of IDC in the first and 
second ET might be that there are two types of IDC that are 
pathologic: one affecting VUR and the other not. 
In this study, DV did not influence the success or 
failure of the initial ET. Regretfully, we could not evaluate 
whether DV affects the success rate of  the second ET 
owing to the small number of patients. Higham-Kessler et 
al. [5] reported that DV might not influence the success or 
failure of the initial ET but could be a factor in a second 
ET (44% DV vs. 14% normal voiding on second injection). 
Therefore, we recommend that it is unnecessary to 
perform pre-ET UDS, but that UDS is essential in deciding 
whether to perform a secondary procedure after the initial 
ET failure. 
A limitation of this study was its retrospective design. 
In cases with remnant VUR, when breakthrough UTI 
or decreased renal function occurred, we were not able to 
exclude the possibility that a secondary procedure would 
have been necessary after ET failure among patients 
in the conservative treatment group. Also, we could not 
distinguish the two types of pathologic IDC. We suggest that 
a prospective, large-scale study will be needed to clarify this 
matter in the future. 
CONCLUSIONS
We suggest that ET-failed patients can be observed for 
spontaneous resolution of  VUR unless they have febrile 
UTI or decreased renal function. We also suggest that UDS 
can be helpful in deciding whether a secondary procedure 
after ET failure is necessary. In cases with IDC, when 
patients need a secondary procedure, we recommend open or 
laparoscopic surgery instead of ET. 
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